Stay updated on NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Sign up to get notified when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.

Latest updates to the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe footer now identifies the website as revision v3.8.0 instead of v3.7.2.SummaryDifference0.0%

- Check24 days agoChange DetectedAn NIH banner announces a terminology change from “Artificial Intelligence” to “Super Intelligence” during a website transition.SummaryDifference0.3%

- Check31 days agoChange DetectedThe ClinicalTrials.gov site footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.0%

- Check37 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1; the study record content remains unchanged.SummaryDifference0.0%

- Check59 days agoChange DetectedThe revision label changes from v3.6.6 to v3.7.0, indicating a software version update. This does not modify the study data, navigation, or visible content on the page.SummaryDifference0.0%

- Check80 days agoChange DetectedThe history now shows a new revision v3.6.6 replacing v3.6.5, signaling a published update to the page's version.SummaryDifference0.0%

Stay in the know with updates to NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer
Enter your email address, and we'll notify you when there's something new on the NILE Clinical Trial: Durvalumab Combo in Unresectable Urothelial Cancer page.